Actualités BioAge Labs Inc - BIOA | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Premium

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal...

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in...

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects...

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a...

BioAge Labs to Present at Upcoming Investor Conferences

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a...

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3...

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage...

BioAge Labs to Present at Jefferies London Healthcare Conference

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage...

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a...

BioAge Labs Announces Pricing of Upsized Initial Public Offering

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

BioAge Labs Inc (BIOA)

Votre Hub pour des idées et discussions en direct en temps réel

BIOA Actualités

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs to Present at Jefferies London Healthcare Conference

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs Announces Pricing of Upsized Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

BioAge Labs Inc (BIOA) Actualités

BioAge Labs Inc (BIOA)

Votre Hub pour des idées et discussions en direct en temps réel

BIOA Actualités

BIOA INVESTOR ALERT: Edelson Lechtzin LLP Urges BioAge Labs, Inc. (NASDAQ: BIOA) Shareholders to Consult Legal Counsel About the Impending Lead Plaintiff Deadline in the Securities Fraud Class Action

BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions

BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity

BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic

BioAge Labs to Present at Upcoming Investor Conferences

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024

BioAge Labs to Present at Jefferies London Healthcare Conference

BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs Announces Pricing of Upsized Initial Public Offering

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités